Modeling the positive symptoms of schizophrenia in genetically modified mice: Pharmacology and methodology aspects

Schizophrenia Bulletin

Volumn 36, Issue 2, 2010, Pages 246-270

  Van Den Buuse, Maarten ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

DISC 1; Dopamine; Dysbindin; Glutamate; Locomotor hyperactivity; Neuregulin 1; Prepulse inhibition; Schizophrenia risk gene

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DYSBINDIN; EXCITATORY AMINO ACID TRANSPORTER 1; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; LAMOTRIGINE; LITHIUM; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; PROTEIN KINASE B; PROTEIN NOGO; QUETIAPINE; RACLOPRIDE; RISPERIDONE; UNINDEXED DRUG;

AUDITORY HALLUCINATION; BEHAVIOR; BIPOLAR DISORDER; CHROMOSOME 22Q; CHROMOSOME DELETION; DELUSION; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; EXPERIMENTAL MODEL; GENETIC SUSCEPTIBILITY; HUMAN; HYPERACTIVITY; KNOCKOUT MOUSE; METHODOLOGY; NONHUMAN; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STARTLE REFLEX;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; GENETIC ASSOCIATION STUDIES; GLUTAMIC ACID; HUMANS; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; PHENOTYPE; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSORY GATING; STARTLE REACTION;

EID: 77749279516     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp132     Document Type: Review

References (284)

1. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature. 2008;40: 827-834.
2. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron. 2006;52:179-196.
3. Chen J, Lipska BK, Weinberger DR. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry. 2006;59:1180-1188.
4. Desbonnet L, Waddington JL, O'Tuathaigh CM. Mutant models for genes associated with schizophrenia. Biochem Soc Trans. 2009;37:308-312.
5. Desbonnet L, Waddington JL, O'Tuathaigh CMP. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes? Behav Brain Res. 2009;204:258-273.
6. Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001;24:527-533.
7. Gogos JA, Gerber DJ. Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends Pharmacol Sci. 2006;27:226-233.
8. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122:593-624.
9. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression. neuropathology: on the matter of their convergence. Mol Psychiatry. 2004;10:40-68.
10. Hunter AJ, Nolan PM, Brown SD. Towards new models of disease and physiology in the neurosciences: the role of induced and naturally occurring mutations. Hum Mol Genet. 2000;9:893-900.
11. O'Tuathaigh CM, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev. 2007;31:60-78.
12. Powell SB, Zhou X, Geyer MA. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res. 2009;204:282-294.
13. Takao K, Yamasaki N, Miyakawa T. Impact of brain-behavior phenotypying of genetically-engineered mice on research of neuropsychiatric disorders. Neurosci Res. 2007;58:124-132.
14. van den Buuse M, Garner B, Gogos A, Kusljic S. Importance of animal models in schizophrenia research. Aust N Z J Psychiatry. 2005;39:550-557.
15. Crawley JN, Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav. 1997;31:197-211.
16. Crawley JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 1999;835:18-26.
17. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry. 2002;7:1039-1053.
18. van der Staay FJ, Steckler T. The fallacy of behavioral phenotyping without standardisation. Genes Brain Behav. 2002;1:9-13.
19. Kalueff AV, Wheaton M, Murphy DL. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res. 2007;179: 1-18.
20. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33:2061-2079.
21. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.
22. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001;49:81-96.
23. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46:56-72.
24. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93: 9235-9240.
25. Di Forti M, Lappin JM, Murray RM. Risk factors for schizophrenia\all roads lead to dopamine. Eur Neuropsy-chopharmacol. 2007;17:S101-S107.
26. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2004;27:1081-1090.
27. Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J, Waddington JL. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology. 1998;37:1595-1602.
28. Paulus MP, Geyer MA. A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology. 1991;104:6-16.
29. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406-433.
30. Creese I, Iversen SD. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res. 1975;83:419-436.
31. Kelly PH, Iversen SD. Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol. 1976;40:45-56.
32. Kuczenski R, Segal DS. In vivo measures of monoamines during amphetamine-induced behaviors in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1991;14:S37-S50.
33. Moore KE. The actions of amphetamine on neurotransmit-ters: a brief review. Biol Psychiatry. 1977;12:451-462.
34. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release do-pamine and serotonin. Synapse. 2001;39:32-41.
35. Koob GF, Caine B, Markou A, Pulvirenti L, Weiss F. Role for the mesocortical dopamine system in the motivating effects of cocaine. NIDA Res Monogr. 1994;145:1-18.
36. Zocchi A, Orsini C, Cabib S, Puglisi-Allegra S. Parallel strain-dependent effect of amphetamine on locomotor activity and dopamine release in the nucleus accumbens: an in vivo study in mice. Neuroscience. 1998;82: 521-528.
37. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev. 2009;60:279-286.
38. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharma-cology. 1999;20:201-225.
39. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003;40:881-884.
40. Tamminga CA, Lahti AC, Medoff DR, Gao XM, Holcomb HH. Evaluating glutamatergic transmission in schizophrenia. Ann N Y Acad Sci. 2003;1003:113-118.
41. Yates JW, Meij JTA, Sullivan JR, Richtand NM, Yu L. Bi-modal effect of amphetamine on motor behaviors in C57BL/ 6 mice. Neurosci Lett. 2007;427:66-70.
42. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000;48:627-640.
43. Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci. 1998;18:5545-5554.
44. Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophe-notypes in order to understand a complex disorder. Schizophr Res. 2007;33:21-32.
45. Geyer MA. Assessing prepulse inhibition of startle in wild-type and knockout mice. Psychopharmacology (Berl). 1999;147:11-13.
46. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995:787-798.
47. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 2001;156: 117-154.
48. Mohr D, Pilz PK, Plappert CF, Fendt M. Accumbal dopa-mine D2 receptors are important for sensorimotor gating in C3H mice. Neuroreport. 2007;18:1493-1497.
49. 2 modulation of sensorimotor gating in rats: assessing anatomical localization. Pharmacol Biochem Behav. 1994;49: 155-163.
50. Gogos A, Bogeski M, Van den Buuse M. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behav Pharmacol. 2008;19:548-561.
51. Paylor R, Crawley JN. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacol-ogy (Berl). 1997;132:169-180.
52. Olivier B, Leahy C, Mullen T, et al. The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsy-chotics? Psychopharmacology (Berl). 2001;156:284-290.
53. Geyer MA, Dulawa SC. Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci. 2003; Chap. 8:Unit 8 17.
54. Dulawa SC, Geyer MA. Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology. 2000;39:2170-2179.
55. Van den Buuse M, Simpson ER, Jones ME. Prepulse inhibition of acoustic startle in aromatase knock-out mice: effects of age and gender. Genes Brain Behav. 2003;2:93-102.
56. 1A receptor stimulation, which are strongly dependent on the genetic background. Psychopharmacology. 2007;195:273-283.
57. z. Psychopharmacology. 2005;183:358-367.
58. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science. 1999;284:1670-1672.
59. Pietropaolo S, Singer P, Feldon J, Yee BK. The postweaning social isolation in C57BL/6 mice: preferential vulnerability in the male sex. Psychopharmacology. 2008;197:613-628.
60. Matthaei K. Genetically manipulated mice: a powerful tool with unsuspected caveats. J Physiol. 2007;582:481-488.
61. 1A dopamine receptors. Proc Natl Acad Sci USA. 1994;91:12564-12568.
62. Xu M, Moratalla R, Gold LH, et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 1994;79:729-742.
63. Xu M, Hu XT, Cooper DC, et al. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysio-logical effects in dopamine D1 receptor mutant mice. Cell. 1994;79:945-955.
64. Centonze D, Grande C, Saulle E, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci. 2003;23:8506-8512.
65. Drago J, Gerfen CR, Westphal H, Steiner H. D1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience. 1996;74:813-823.
66. Crawford CA, Drago J, Watson JB, Levine MS. Effects of repeated amphetamine treatment on the locomotor activity of the dopamine D1A-deficient mouse. Neuroreport. 1997;8:2523-2527.
67. Xu M, Guo Y, Vorhees CV, Zhang J. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res. 2000;852:198-207.
68. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci. 2002;22:9604-9611.
69. Doherty JM, Masten VL, Powell SB, et al. Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology. 2008;33:2648-2656.
70. Dracheva S, Xu M, Kelley KA, et al. Paradoxical locomotor behavior of dopamine D1 receptor transgenic mice. Exp Neurol. 1999;157:169-179.
71. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 1995;377:424-428.
72. Clifford JJ, Usiello A, Vallone D, Kinsella A, Borrelli E, Waddington JL. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D2 dopamine receptor. Neuropharmacology. 2000;39: 382-390.
73. Kelly MA, Rubinstein M, Phillips TJ, et al. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci. 1998;18:3470-3479.
74. Chausmer AL, Elmer GI, Rubinstein M, Low MJ, Grandy DK, Katz JL. Cocaine-induced locomotor activity and cocaine discrimination in dopamine D2 receptor mutant mice. Psychopharmacology (Berl). 2002;163:54-61.
75. Kelly MA, Low MJ, Rubinstein M, Phillips TJ. Role of do-pamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice. Genes Brain Behav. 2008;7:568-577.
76. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA. Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology. 2006;31:2349-2358.
77. Clifford JJ, Kinsella A, Tighe O, et al. Comparative, topographically-based evaluation of behavioural phenotype and specification of D(1)-like:D(2) interactions in a line of incipient congenic mice with D(2) dopamine receptor 'knockout'. Neuropsychopharmacology. 2001;25:527-536.
78. Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, Croke DT. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:925-964.
79. Kellendonk C, Simpson EH, Polan HJ, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006;49:603-615.
80. Usiello A, Baik JH, Rouge-Pont F, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000;408:199-203.
81. Xu R, Hranilovic D, Fetsko LA, Bucan M, Wang Y. Dopa-mine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol Psychiatry. 2002;7:1075-1082.
82. Wang Y, Xu R, Sasaoka T, Tonegawa S, Kung MP, Sankoorikal EB. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci. 2000;20:8305-8314.
83. Ralph RJ, Varty GB, Kelly MA, et al. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci. 1999;19:4627-4633.
84. Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyper-activity in mice. Proc Natl Acad Sci USA. 1996;93: 1945-1949.
85. Joseph JD, Wang YM, Miles PR, et al. Dopamine autore-ceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience. 2002;112:39-49.
86. Xu M, Koeltzow TE, Santiago GT, et al. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 1997;19:837-848.
87. Jung MY, Skryabin BV, Arai M, et al. Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors. Neuroscience. 1999;91:911-924.
88. McNamara RK, Logue A, Stanford K, Xu M, Zhang J, Richtand NM. Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse. 2006;60:399-405.
89. Le Foll B, Frances H, Diaz J, Schwartz JC, Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci. 2002;15:2016-2026.
90. Leriche L, Schwartz JC, Sokoloff P. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology. 2003;45: 174-181.
91. Rubinstein M, Phillips TJ, Bunzow JR, et al. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 1997;90:991-1001.
92. Katz JL, Chausmer AL, Elmer GI, Rubinstein M, Low MJ, Grandy DK. Cocaine-induced locomotor activity and cocaine discrimination in dopamine D4 receptor mutant mice. Psychopharmacology (Berl). 2003;170:108-114.
93. Kruzich PJ, Suchland KL, Grandy DK. Dopamine D4 receptor-deficient mice, congenic on the C57BL/6J background, are hypersensitive to amphetamine. Synapse. 2004;53:131-139.
94. Thanos P, Bermeo C, Rubinstein M, et al. Conditioned place preference and locomotor activity in response to meth-ylphenidate, amphetamine and cocaine in mice lacking dopamine D4 receptors. J Psychopharmacol. 2009; In press.
95. Holmes A, Hollon TR, Gleason TC, et al. Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci. 2001;115:1129-1144.
96. Elliot EE, Sibley DR, Katz JL. Locomotor and discriminative-stimulus effects of cocaine in dopamine D5 receptor knockout mice. Psychopharmacology (Berl). 2003;169: 161-168.
97. Karlsson RM, Hefner KR, Sibley DR, Holmes A. Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization. Psychopharmacology (Berl). 2008;200:117-127.
98. Gainetdinov RR. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:301-313.
99. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379:606-612.
100. Morice E, Denis C, Giros B, Nosten-Bertrand M. Pheno-typic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur J Neurosci. 2004;20:120-126.
101. Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci. 2001;21: 305-313.
102. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Gluta-matergic modulation of hyperactivity in mice lacking the do-pamine transporter. Proc Natl Acad Sci USA. 2001;98: 11047-11054.
103. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 1999;283:397-401.
104. Gainetdinov RR, Caron MG. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol. 2003;43:261-284.
105. Zhuang X, Oosting RS, Jones SR, et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA. 2001;98:1982-1987.
106. Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry. 2003;53:352-359.
107. Tilley MR, Cagniard B, Zhuang X, Han DD, Tiao N, Gu HH. Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression. BMC Neuro-sci. 2007;8:42.
108. Enomoto T, Noda Y, Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol. 2007;29:291-301.
109. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 1999;98:427-436.
110. Forrest D, Yuzaki M, Soares HD, et al. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron. 1994;13: 325-338.
111. Duncan GE, Moy SS, Lieberman JA, Koller BH. Typical and atypical antipsychotic drug effects on locomotor hyper-activity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol Biochem Behav. 2006;85:481-491.
112. Bickel S, Lipp HP, Umbricht D. Impaired attentional modulation of auditory evoked potentials in N-methyl-D-aspartate NR1 hypomorphic mice. Genes Brain Behav. 2007;6:558-568.
113. Bickel S, Lipp HP, Umbricht D. Early auditory sensory processing deficitsin mouse mutants with reduced NMDA receptor function. Neuropsychopharmacology. 2008;33:1680-1689.
114. Fradley RL, O'Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS. STOP knockout and NMDA NR1 hypomor-phic mice exhibit deficits in sensorimotor gating. Behav Brain Res. 2005;163:257-264.
115. Duncan GE, Moy SS, Lieberman JA, Koller BH. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology (Berl). 2006;184:190-200.
116. Moy SS, Perez A, Koller BH, Duncan GE. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res. 2006;1089:186-194.
117. Ohtsuka N, Tansky MF, Kuang H, et al. Functional disturbances in the striatum by region-specific ablation of NMDA receptors. Proc Natl Acad Sci USA. 2008;105: 12961-12966.
118. Cui Z, Wang H, Tan Y, Zaia KA, Zhang S, Tsien JZ. Induc-ible and reversible NR1 knockout reveals crucial role of the NMDA receptor in preserving remote memories in the brain. Neuron. 2004;41:781-793.
119. Dang MT, Yokoi F, Yin HH, Lovinger DM, Wang Y, Li Y. Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proc Natl Acad Sci USA. 2006;103:15254-15259.
120. Heusner CL, Palmiter RD. Expression of mutant NMDA receptors in dopamine D1 receptor-containing cells prevents cocaine sensitization and decreases cocaine preference. J Neurosci. 2005;25:6651-6657.
121. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and seroto-nergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci. 2001;21:750-757.
122. Ikeda K, Araki K, Takayama C, et al. Reduced spontaneous activity of mice defective in the epsilon 4 subunit of the NMDA receptor channel. Brain Res Mol Brain Res. 1995;33:61-71.
123. Ebralidze AK, Rossi DJ, Tonegawa S, Slater NT. Modification of NMDA receptor channels and synaptic transmission by targeted disruption of the NR2C gene. J Neurosci. 1996;16:5014-5025.
124. Kadotani H, Hirano T, Masugi M, et al. Motor discoordina-tion results from combined gene disruption of the NMDA receptor NR2A and NR2C subunits, but not from single disruption of the NR2A or NR2C subunit. J Neurosci. 1996;16:7859-7867.
125. Takeuchi T, Kiyama Y, Nakamura K, et al. Roles of the glutamate receptor epsilon2 and delta2 subunits in the potentiation and prepulse inhibition of the acoustic startle reflex. Eur J Neurosci. 2001;14:153-160.
126. Brody SA, Nakanishi N, Tu S, Lipton SA, Geyer MA. A developmental influence of the N-methyl-D-aspartate receptor NR3A subunit on prepulse inhibition of startle. Biol Psychiatry. 2005;57:1147-1152.
127. Kew JN, Koester A, Moreau JL, et al. Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J Neurosci. 2000;20:4037-4049.
128. Ballard TM, Pauly-Evers M, Higgins GA, et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci. 2002;22:6713-6723.
129. Karlsson RM, Tanaka K, Heilig M, Holmes A. Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol Psychiatry. 2008;64:810-814.
130. Karlsson R-M, Tanaka K, Saksida LM, Bussey TJ, Heilig M, Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology. 2009;34:1578-1589.
131. Wiedholz LM, Owens WA, Horton RE, et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminer-gia and 'schizophrenia-related' behaviors. Mol Psychiatry. 2008;13:631-640.
132. Pietraszek M, Nagel J, Gravius A, Schafer D, Danysz W. The role of group I metabotropic glutamate receptors in schizophrenia. Amino Acids. 2007;32:173-178.
133. Conquet F, Bashir ZI, Davies CH, et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature. 1994;372:237-243.
134. Aiba A, Kano M, Chen C, et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell. 1994;79:377-388.
135. Mao L, Conquet F, Wang JQ. Augmented motor activity and reduced striatal preprodynorphin mRNA induction in response to acute amphetamine administration in metabo-tropic glutamate receptor 1 knockout mice. Neuroscience. 2001;106:303-312.
136. Brody SA, Conquet F, Geyer MA. Disruption of prepulse inhibition in mice lacking mGluR1. Eur J Neurosci. 2003;18:3361-3366.
137. Chiamulera C, Epping-Jordan MP, Zocchi A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001;4:873-874.
138. Kinney GG, Burno M, Campbell UC, et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther. 2003;306:116-123.
139. Brody SA, Dulawa SC, Conquet F, Geyer MA. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry. 2004;9:35-41.
140. Brody SA, Conquet F, Geyer MA. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl). 2004;172:187-195.
141. Brody SA, Geyer MA. Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotox Res. 2004;6:79-90.
142. Lipina T, Weiss K, Roder J. The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice. Neuropsychopharmacology. 2007;32:745-756.
143. Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol. 2009;12:45-60.
144. Morishima Y, Miyakawa T, Furuyashiki T, Tanaka Y, Mizuma H, Nakanishi S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic gluta-mate receptor subtype 2 knockout mice. Proc Natl Acad Sci USA. 2005;102:4170-4175.
145. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol. 2008;22:308-322.
146. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl). 2008;196:431-440.
147. Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol. 2000;397: R1-R2.
148. Yokoi M, Kobayashi K, Manabe T, et al. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science. 1996;273:645-647.
149. Corti C, Battaglia G, Molinaro G, et al. The use of knockout mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neuro-degeneration/neuroprotection. J Neurosci. 2007;27:8297-8308.
150. Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3. 1. 0]hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther. 2008;326:209-217.
151. Seeman P, Battaglia G, Corti C, Corsi M, Bruno V. Gluta-mate receptor mGlu2 and mGlu3 knockout striata are dopa-mine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse. 2009;63:247-251.
152. Bertram L. Genetic research in schizophrenia: new tools and future perspectives. Schizophr Bull. 2008;34:806-812.
153. Roffman JL, Weiss AP, Purcell S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63:42-48.
154. Nakamura K, Koyama Y, Takahashi K, et al. Requirement of tryptophan hydroxylase during development for maturation of sensorimotor gating. J Mol Biol. 2006;363:345-354.
155. Patel PD, Pontrello C, Burke S. Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biol Psychiatry. 2004;55:428-433.
156. Zill P, Buttner A, Eisenmenger W, Moller HJ, Ackenheil M, Bondy B. Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. J Psychiatr Res. 2007;41:168-173.
157. Savelieva KV, Zhao S, Pogorelov VM, et al. Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS One. 2008;3:e3301.
158. Williams NM, O'Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull. 2005;31:800-805.
159. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem. 2001;276:24232-24241.
160. Li W, Zhang Q, Oiso N, et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet. 2003;35:84-89.
161. Hattori S, Murotani T, Matsuzaki S, et al. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun. 2008;373:298-302.
162. Feng YQ, Zhou ZY, He X, et al. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr Res. 2008;106:218-228.
163. Takao K, Toyama K, Nakanishi K, et al. Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol Brain. 2008;1:11.
164. Bhardwaj SK, Baharnoori M, Sharif-Askari B, Kamath A, Williams S, Srivastava LK. Behavioral characterization of dysbindin-1 deficient sandy mice. Behav Brain Res. 2009;197:435-441.
165. Murotani T, Ishizuka T, Hattori S, Hashimoto R, Matsuzaki S, Yamatodani A. High dopamine turnover in the brains of Sandy mice. Neurosci Lett. 2007;421:47-51.
166. Chen XW, Feng YQ, Hao CJ, et al. DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J Cell Biol. 2008;181:791-801.
167. Cox MM, Tucker AM, Tang J, et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav. 2009;8:390-397.
168. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877-892.
169. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14-30.
170. O'Tuathaigh CM, Desbonnet L, Waddington JL. Neuregulin-1 signaling in schizophrenia: 'Jack of all trades' or master of some? Expert Rev Neurother. 2009;9:1-3.
171. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60:132-140.
172. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437-452.
173. O'Tuathaigh CM, O'Sullivan GJ, Kinsella A, et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuro-report. 2006;17:79-83.
174. Karl T, Duffy L, Scimone A, Harvey RP, Schofield PR. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav. 2007;6:677-687.
175. van den Buuse M, Wischhof L, Xi Lee R, Martin S, Karl T. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol. 2009;12:1383-1393.
176. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of D9-tetrahydrocannabinol. Psychopharmacology (Berl). 2007;192:325-336.
177. Duffy L, Cappas E, Scimone A, Schofield PR, Karl T. Behavioral profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1. Behav Neurosci. 2008;122:748-759.
178. Rimer M, Barrett DW, Maldonado MA, Vock VM, Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport. 2005;16:271-275.
179. Chen YJ, Johnson MA, Lieberman MD, et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci. 2008;28:6872-6883.
180. Gerlai R, Pisacane P, Erickson S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res. 2000;109: 219-227.
181. Golub MS, Germann SL, Lloyd KC. Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav Brain Res. 2004;153:159-170.
182. Thuret S, Alavian KN, Gassmann M, et al. The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta. J Neurochem. 2004;91:1302-1311.
183. Hu X, Hicks CW, He W, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520-1525.
184. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA. 2008;105:5585-5590.
185. Dejaegere T, Serneels L, Schafer MK, et al. Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sen-sorimotor gating that can be reversed with antipsychotic treatment. Proc Natl Acad Sci USA. 2008;105:9775-9780.
186. Roberts RC. Schizophrenia in translation: disrupted in schizophrenia (DISC1): integrating clinical and basic findings. Schizophr Bull. 2007;33:11-15.
187. Muir WJ, Pickard BS, Blackwood DH. Disrupted-in-schizophrenia-1. Curr Psychiatry Rep. 2008;10:140-147.
188. Koike H, Arguello PA, Kvajo M, Karayiorgou M, Gogos JA. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc Natl Acad Sci USA. 2006;103:3693-3697.
189. Clapcote SJ, Roder JC. Deletion polymorphism of Disc1 is common to all 129 mouse substrains: implications for gene-targeting studies of brain function. Genetics. 2006;173:2407-2410.
190. Clapcote SJ, Lipina TV, Millar JK, et al. Behavioral pheno-types of Disc1 missense mutations in mice. Neuron. 2007;54:387-402.
191. Hikida T, Jaaro-Peled H, Seshadri S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA. 2007;104:14501-14506.
192. Li W, Zhou Y, Jentsch JD, et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci USA. 2007;104:18280-18285.
193. Kvajo M, McKellar H, Arguello PA, et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci USA. 2008;105:7076-7081.
194. Pletnikov MV, Ayhan Y, Nikolskaia O, et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry. 2008;13:173-186 115.
195. Millar JK, Mackie S, Clapcote SJ, et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol. 2007;584: 401-405.
196. Siuciak JA, McCarthy SA, Chapin DS, Martin AN. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharma-cology (Berl). 2008;197:115-126.
197. Mao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell. 2009;136: 1017-1031.
198. Gould TD, O'Donnell KC, Picchini AM, Dow ER, Chen G, Manji HK. Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. Behav Brain Res. 2008;189:117-125.
199. Gould TD, Einat H, O'Donnell KC, Picchini AM, Schloesser RJ, Manji HK. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology. 2007;32:2173-2183.
200. Beaulieu J-M, Caron MG. Looking at lithium: molecular moods and complex behaviour. Mol Interv. 2008;8:230-241.
201. Amar S, Jones BC, Nadri C, Kozlovsky N, Belmaker RH, Agam G. Genetic correlational analysis of glycogen synthase kinase-3 beta and prepulse inhibition in inbred mice. Genes Brain Behav. 2004;3:178-180.
202. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci. 2004;24: 6791-6798.
203. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA. 2008;105:1333-1338.
204. Bersudsky Y, Shaldubina A, Kozlovsky N, Woodgett JR, Agam G, Belmaker RH. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav Pharmacol. 2008;19:217-224.
205. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/ glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA. 2004;101:5099-5104.
206. Beaulieu J-M, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci. 2007;28:166-172.
207. Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci. 2006;26:9022-9029.
208. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3b signaling in schizophrenia. Nat Genet. 2004;36: 131-137.
209. Koros E, Dorner-Ciossek C. The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect. 2007;20: 437-445.
210. Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007;30:142-149.
211. Arinami T. Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J Hum Genet. 2006;51:1037-1045.
212. Prasad SE, Howley S, Murphy KC. Candidate genes and the behavioral phenotype in 22q11. 2 deletion syndrome. Dev Disabil Res Rev. 2008;14:26-34.
213. Karayiorgou M, Gogos JA. The molecular genetics of the 22q11-associated schizophrenia. Brain Res Mol Brain Res. 2004;132:95-104.
214. Paylor R, Lindsay E. Mouse models of 22q11 deletion syndrome. Biol Psychiatry. 2006;59:1172-1179.
215. Paylor R, McIlwain KL, McAninch R, et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum Mol Genet. 2001;10:2645-2650.
216. Gogos JA, Santha M, Takacs Z, et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet. 1999;21:434-439.
217. Mukai J, Liu H, Burt RA, et al. Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet. 2004;36:725-731.
218. Paterlini M, Zakharenko SS, Lai WS, et al. Transcriptional and behavioral interaction between 22q11. 2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neuro-sci. 2005;8:1586-1594.
219. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase- deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA. 1998;95:9991-9996.
220. Huotari M, Garcia-Horsman JA, Karayiorgou M, Gogos JA, Mannisto PT. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharma-cology (Berl). 2004;172:1-10.
221. Huotari M, Santha M, Lucas LR, Karayiorgou M, Gogos JA, Mannisto PT. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther. 2002;303:1309-1316.
222. Papaleo F, Crawley JN, Song J, et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci. 2008;28:8709-8723.
223. Paylor R, Glaser B, Mupo A, et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci USA. 2006;103:7729-7734.
224. Long JM, LaPorte P, Merscher S, et al. Behavior of mice with mutations in the conserved region deleted in velocar-diofacial/DiGeorge syndrome. Neurogenetics. 2006;7:247-257.
225. Hsu R, Woodroffe A, Lai WS, et al. Nogo receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS ONE. 2007;2:e1234.
226. Kim JE, Liu BP, Park JH, Strittmatter SM. Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron. 2004;44:439-451.
227. Willi R, Aloy EM, Yee BK, Feldon J, Schwab ME. Behavioral characterization of mice lacking the neurite outgrowth inhibitor Nogo-A. Genes Brain Behav. 2009;8:181-192.
228. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6:312-324.
229. Heldt SA, Green A, Ressler KJ. Prepulse inhibition deficits in GAD65 knockout mice and the effect of antipsychotic treatment. Neuropsychopharmacology. 2004;29:1610-1619.
230. Yee BK, Keist R, von Boehmer L, et al. A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci USA. 2005;102:17154-17159.
231. Rudolph U, Mohler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol. 2006;6:18-23.
232. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl). 2004;174:143-150.
233. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry. 2003;27: 1159-1172.
234. Roth BL, Meltzer HY. The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995:1215-1227.
235. Dulawa SC, Gross C, Stark KL, Hen R, Geyer M.A. Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition. Neuropsychopharmacology. 2000;22:650-659. (Pubitemid 30219408)
236. Dulawa SC, Scearce-Levie KA, Hen R, Geyer MA. Serotonin releasers increase prepulse inhibition in serotonin 1B knockout mice. Psychopharmacology (Berl). 2000;149:306-312. (Pubitemid 30262345)
237. Gonzalez-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53: 439-452.
238. Grailhe R, Waeber C, Dulawa SC, et al. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron. 1999;22:581-591.
239. 2C receptors exert opposing effects on loco-motor activity in mice. Neuropsychopharmacology. 2009; 34:1958-1967.
240. 7 receptor partially blocks phencycli-dine-induced disruption ofprepulse inhibition. Biol Psychiatry. 2008;63:98-105.
241. Felder CC, Porter AC, Skillman TL, et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 2001;68:2605-2613.
242. Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neuro-chem. 2008;107:1188-1195.
243. 5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Recept Channels. 2003;9:279-290. (Pubitemid 37069448)
244. Wess J, Eglen RM, Gautam D. Muscarinic acetylcho-line receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007;6: 721-733.
245. Angelucci F, Brene S, Mathe AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;10:345-352.
246. Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci. 1999;19:4110-4122.
247. Hall FS, Drgonova J, Goeb M, Uhl GR. Reduced behavioral effects of cocaine in heterozygous brain-derived neuro-trophic factor (BDNF) knockoutmice. Neuropsychopharmacology. 2003;28:1485-1490.
248. Dluzen DE, Gao X, Story GM, Anderson LI, Kucera J, Walro JM. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/ BDNF mutant mice. Exp Neurol. 2001;170:121-128.
249. Saylor AJ, McGinty JF. Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice. Genes Brain Behav. 2008;7:906-914.
250. Gorski JA, Balogh SA, Wehner JM, Jones KR. Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience. 2003;121:341-354.
251. Autry AE, Adachi M, Cheng P, Monteggia LM. Gender-specific impact of brain-derived neurotrophic factor signaling on stress-induced depression-like behavior. Biol Psychiatry. 2009;66:84-90.
252. Monteggia LM, Luikart B, Barrot M, et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry. 2007;61:187-197.
253. Monteggia LM, Barrot M, Powell CM, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA. 2004;101:10827-10832.
254. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 2000;19:1290-1300.
255. Rios M, Fan G, Fekete C, et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol. 2001;15:1748-1757.
256. Chen ZY, Jing D, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314:140-143.
257. Costa E, Chen Y, Davis J, et al. REELIN and schizophrenia: a disease at the interface of the genome and the epige-nome. Mol Interv. 2002;2:47-57.
258. Tueting P, Doueiri MS, Guidotti A, Davis JM, Costa E. Reelin down-regulation in mice and psychosis endopheno-types. Neurosci Biobehav Rev. 2006;30:1065-1077.
259. Impagnatiello F, Guidotti AR, Pesold C, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA. 1998;95:15718-15723.
260. Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C. Dendritic spine hypoplasticity and downregula-tion of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis. 2001;8:723-742.
261. Pappas GD, Kriho V, Pesold C. Reelin in the extracellular matrix and dendritic spines of the cortex and hippocampus: a comparison between wild type and heterozygous reeler mice by immunoelectron microscopy. J Neurocytol. 2001;30:413-425.
262. Matsuzaki H, Minabe Y, Nakamura K, et al. Disruption of reelin signaling attenuates methamphetamine-induced hyperlocomotion. Eur J Neurosci. 2007;25:3376-3384.
263. Ognibene E, Adriani W, Caprioli A, et al. The effect of early maternal separation on brain derived neurotrophic factor and monoamine levels in adult heterozygous reeler mice. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 1269-1276.
264. Salinger WL, Ladrow P, Wheeler C. Behavioral phenotype of the reeler mutant mouse: effects of RELN gene dosage and social isolation. Behav Neurosci. 2003;117: 1257-1275.
265. Tueting P, Costa E, Dwivedi Y, et al. The phenotypic characteristics of heterozygous reeler mouse. Neuroreport. 1999;10:1329-1334.
266. Varty GB, Powell SB, Lehmann-Masten V, Buell MR, Geyer MA. Isolation rearing of mice induces deficits in pre-pulse inhibition of the startle response. Behav Brain Res. 2006;169:162-167.
267. Barr AM, Fish KN, Markou A, Honer WG. Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins. Eur J Neurosci. 2008;27:2568-2574.
268. Podhorna J, Didriksen M. The heterozygous reeler mouse: behavioural phenotype. Behav Brain Res. 2004;153:43-54.
269. Eells JB, Lipska BK, Yeung SK, Misler JA, Nikodem VM. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav Brain Res. 2002;136:267-275.
270. Eells JB, Misler JA, Nikodem VM. Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in Nurr1-null heterozygous mice. Neuroscience. 2006;140:1117-1126.
271. Rojas P, Joodmardi E, Hong Y, Perlmann T, Ogren SO. Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol Psychiatry. 2007;12:756-766.
272. Zeng H, Chattarji S, Barbarosie M, et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synap-tic plasticity and working/episodic-like memory. Cell. 2001;107:617-629.
273. Miyakawa T, Leiter LM, Gerber DJ, et al. Conditional cal-cineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA. 2003;100:8987-8992.
274. Grillet N, Pattyn A, Contet C, Kieffer BL, Goridis C, Brunet JF. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol. 2005;25:4221-4228.
275. Harrison SM, Reavill C, Brown G, et al. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci. 2003;24:1170-1179.
276. Irintchev A, Koch M, Needham LK, Maness P, Schachner M. Impairment of sensorimotor gating in mice deficient in the cell adhesion molecule L1 or its close homologue, CHL1. Brain Res. 2004;1029:131-134.
277. Pillai-Nair N, Panicker AK, Rodriguiz RM, et al. Neural cell adhesion molecule-secreting transgenic mice display abnormalities in GABAergic interneurons and alterations in behavior. J Neurosci. 2005;25:4659-4671.
278. Roberts C, Winter P, Shilliam CS, et al. Neurochemical changes in LPA1 receptor deficient mice\a putative model of schizophrenia. Neurochem Res. 2005;30:371-377.
279. van den Buuse M, Zheng TW, Walker LL, Denton DA. An-giotensin-converting enzyme (ACE) interacts with dopami-nergic mechanisms in the brain to modulate prepulse inhibition in mice. Neurosci Lett. 2005;380:6-11.
280. Caldwell HK, Stephens SL, Young WS, 3rd. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry. 2009;14:190-196.
281. Bertrand PP, Paranavitane UT, Chavez C, Gogos A, Jones M, van den Buuse M. The effect of low estrogen state on serotonin transporter function in mouse hippocampus: a behavioral and electrochemical study. Brain Res. 2005;1064:10-20.
282. Kelly MP, Stein JM, Vecsey CG, et al. Developmental etiology for neuroanatomical and cognitive deficits in mice over-expressing Galphas, a G-protein subunit genetically linked to schizophrenia. Mol Psychiatry. 2009;14:398-415 347.
283. Hashimoto R, Hashimoto H, Shintani N, et al. Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry. 2007;12:1026-1032.
284. Szumlinski KK, Lominac KD, Kleschen MJ, et al. Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav. 2005;4:273-288.